Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL15008876 | 0.97 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL3302667 | 0.97 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL22701318 | 0.94 | SLC6A3 (0.35) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL14160126 | 0.91 | HRH3 (0.40) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL2229569 | 0.90 | SLC6A3 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL24869964 | 0.89 | HRH3 (0.42) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL14204509 | 0.89 | HRH3 (0.42) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL21164045 | 0.89 | HRH3 (0.42) | SLC6A3SLC6A2SLC6A4HRH3 | |
| SCHEMBL8494598 | 0.89 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL18403963 | 0.89 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295096-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116635228-A | Surface protective film | 日东电工株式会社 | 2023-08-22 | — | — | CN | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11413682-B2 | Method for producing surface-modified metal oxide fine particle, method for producing improved metal oxide fine particles, surface-modified metal oxide fine particles, and metal oxide fine particle dispersion liquid | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3998339-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20200139433-A1 | METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE FINE PARTICLE, METHOD FOR PRODUCING IMPROVED METAL OXIDE FINE PARTICLES, SURFACE-MODIFIED METAL OXIDE FINE PARTICLES, AND METAL OXIDE FINE PARTICLE DISPERSION LIQUID | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| CN-110476003-A | Heat-insulated insulation substrate | NITTO DENKO CORP | 2019-11-19 | — | — | CN | disclosed |
| CN-107074890-B | Alkenyl (perfluoroalkyl) phosphinic acids | 默克专利股份公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-104342049-B | Bonding sheet and optical component | 日东电工株式会社 | 2019-07-23 | — | — | CN | disclosed |
| CN-104342050-B | Bonding sheet and optical component | 日东电工株式会社 | 2019-06-07 | — | — | CN | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| EP-1628957-B1 | SULFOPYRROLES | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | SLC6A3 3398/4885SLC6A2 2532/4885SLC6A4 2305/4885 |
| US-20230295096-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | SLC6A3 4869/4885SLC6A2 4874/4885SLC6A4 4804/4885 |
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | SLC6A3 3486/4885SLC6A2 4023/4885SLC6A4 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.